Literature DB >> 20884740

Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension.

N Gambaryan1, F Perros, D Montani, S Cohen-Kaminsky, M Mazmanian, J-F Renaud, G Simonneau, A Lombet, M Humbert.   

Abstract

Haematopoietic c-kit+ progenitor cells may contribute to pulmonary vascular remodelling and pulmonary hypertension (PH). Stromal derived factor-1 (SDF-1/CXCL12) and its receptors CXCR4 and CXCR7 have been shown to be critical for homing and mobilisation of haematopoietic c-kit+ progenitor cells in the perivascular niche. We administered AMD3100, a CXCR4 antagonist, and CCX771, a CXCR7 antagonist, to chronic hypoxia exposed mice in order to study the role of c-kit+ progenitor cells in PH. CXCL12, CXCR4 and CXCR7 protein expression, haemodynamic parameters, right ventricular mass, extent of vascular remodelling and perivascular progenitor cell accumulation were studied. Chronic hypoxia-exposed mice showed increased total lung tissue expression of CXCR4, CXCR7 and CXCL12 after development of PH. This was associated with significantly increased right ventricular systolic pressure and evidence of right ventricular hypertrophy, vascular remodelling and perivascular c-kit+/sca-1+ progenitor cell accumulation. CCX771 administration did not abrogate these effects. In contrast, administration of AMD3100, whether alone or combined with CCX771, prevented vascular remodelling, PH and perivascular accumulation of c-kit+/sca-1+ progenitor cells, with a synergistic effect of these agents. This study offers important pathophysiological insights into the role of haematopoietic c-kit+ progenitors in hypoxia-induced vascular remodelling and may have therapeutic implications for PH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20884740     DOI: 10.1183/09031936.00045710

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  42 in total

1.  Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.

Authors:  Rubin M Tuder; Laura A Davis; Brian B Graham
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

2.  Pharmacological targeting of chemokine (C-X-C motif) receptor 4 in porcine polytrauma and hemorrhage models.

Authors:  Harold H Bach; Yee M Wong; Heather M LaPorte; Richard L Gamelli; Matthias Majetschak
Journal:  J Trauma Acute Care Surg       Date:  2016-01       Impact factor: 3.313

3.  ID3 contributes to the acquisition of molecular stem cell-like signature in microvascular endothelial cells: its implication for understanding microvascular diseases.

Authors:  Jayanta K Das; Norbert F Voelkel; Quentin Felty
Journal:  Microvasc Res       Date:  2015-02-07       Impact factor: 3.514

4.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension.

Authors:  Min Li; Suzette R Riddle; Maria G Frid; Karim C El Kasmi; Timothy A McKinsey; Ronald J Sokol; Derek Strassheim; Barbara Meyrick; Michael E Yeager; Amanda R Flockton; B Alexandre McKeon; Douglas D Lemon; Todd R Horn; Adil Anwar; Carlos Barajas; Kurt R Stenmark
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

6.  Bone Marrow-Derived Proangiogenic Cells Mediate Pulmonary Arteriole Stiffening via Serotonin 2B Receptor Dependent Mechanism.

Authors:  Nathaniel C Bloodworth; Cynthia R Clark; James D West; J Caleb Snider; Christa Gaskill; Sheila Shay; Christine Scott; Julie Bastarache; Santhi Gladson; Christy Moore; Reid D'Amico; Evan L Brittain; Harikrishna Tanjore; Timothy S Blackwell; Susan M Majka; W David Merryman
Journal:  Circ Res       Date:  2018-12-07       Impact factor: 17.367

7.  Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels.

Authors:  Robert D Berahovich; Brian A Zabel; Susanna Lewén; Matthew J Walters; Karen Ebsworth; Yu Wang; Juan C Jaen; Thomas J Schall
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

8.  Imatinib in pulmonary arterial hypertension: c-Kit inhibition.

Authors:  Samar Farha; Raed Dweik; Franck Rahaghi; Raymond Benza; Paul Hassoun; Robert Frantz; Fernando Torres; Deborah A Quinn; Suzy Comhair; Serpil Erzurum; Kewal Asosingh
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

Review 9.  Origin and production of inflammatory perivascular macrophages in pulmonary hypertension.

Authors:  Jonathan Florentin; Partha Dutta
Journal:  Cytokine       Date:  2017-08-30       Impact factor: 3.861

Review 10.  Vascular repair and regeneration as a therapeutic target for pulmonary arterial hypertension.

Authors:  Laszlo Farkas; Martin Kolb
Journal:  Respiration       Date:  2013-03-22       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.